Celgene
Corporate Headquarters
86 Morris Avenue
Summit
New Jersey
07901
United States
Tel: 908-673-9000
Fax: 908-673-9001
Website: http://www.celgene.com/
About Celgene
At Celgene Corporation, we’re committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first. As a global leader in biotechnology and CAR T cell therapy, Celgene is a place where employees can make a real impact on the lives of patients with unmet medical needs in cancer and inflammatory diseases.
As we rapidly advance our next wave of innovative medicines, we announce the creation of a new global Clinical Development Organization to accelerate and optimize clinical development across our entire mid- to late-stage portfolio. Our commitments in this area will further establish the function as a center of excellence and enhance our strategic leadership in discovery, development and commercialization.
Recognized by Forbes in 2018 as a Top 10 World’s Best Employer and by Business Insider as the #3 Most Reputable Pharma Company in the World, Celgene offers a unique work environment where you can help build the business, while building your career in ways you may not have thought possible. We’re looking for innovative self-starters who want to improve the lives of patients worldwide. For more information, visit https://www.celgene.com/careers/.
CAR T cell therapy is a groundbreaking immunotherapy treatment that leverages a patient’s own immune system in fighting their cancer. Celgene is looking for dedicated people to join our team in this exciting area of cancer treatment.
1081 articles with Celgene
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes - Sept. 23, 2019
9/23/2019
Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.
-
Clinical Catch-Up: September 16-20
9/23/2019
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories. -
Celgene Corporation Names Second Round of Celgene Cancer Care Links™ Program Grant Recipients
9/20/2019
Celgene Corporation (NASDAQ: CELG) today announced an additional ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support healthcare capacity building in resource-constrained countries around the world.
-
Celgene announced topline data from its Phase III QUAZAR AML-001 trial.
-
Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints
9/12/2019
Celgene Corporation announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
-
Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
9/9/2019
Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms of multiple sclerosis (RMS), at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11-13, 2019.
-
In the first two weeks of September there were three scheduled PDUFA dates. One of those dates, for Celgene’s myelofibrosis drug, was approved early. Here’s a look.
-
DarwinHealth Announces Compound-2-Clinic (C2C) Scientific Collaboration with Celgene to Deploy a Quantitative Systems Biology Discovery Platform to Characterize Celgene Oncology Compounds
8/28/2019
DarwinHealth today announced a multi-year scientific research collaboration with Celgene Corporation ("Celgene") to use quantitative systems biology-based algorithms, technologies that also underpin NY State CLIA-approved diagnostic tests in oncology, and novel, validated approaches focused on tumor checkpoint-targeted therapy to support Celgene's clinical development efforts with respect to certain specified compounds.
-
The two companies struck a strategic collaboration and option agreement to harness the power of Immatics’ T-Cell Receptor Engineered T-cell Therapy programs and aim them at solid tumors.
-
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
8/26/2019
Bristol-Myers Squibb Company announced that Celgene Corporation, in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen under which Amgen would acquire the global rights to OTEZLA® for $13.4 billion in cash.
-
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
8/26/2019
Amgen announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire worldwide rights to Otezla®, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.
-
BMS and Celgene first announced the probable sale of the asset earlier this summer as a means to smooth out the anti-trust review process of the merger from the Federal Trade Commission.
-
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
-
Onco360® Selected to Dispense Inrebic® (fedratinib)
8/16/2019
Onco360®, the nation’s largest independent Oncology Pharmacy, announced today that it was selected to be a specialty pharmacy network partner for Celgene’s new product Inrebic® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF)
-
The U.S. Food and Drug Administration approved Impact’s Inrebic for the treatment for adult patients with certain types of myelofibrosis, cancers of the bone marrow.
-
Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
7/31/2019
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
-
Celgene Reports Second Quarter 2019 Operating and Financial Results
7/30/2019
Celgene Corporation reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.
-
Celgene and the Multiple Sclerosis Association of America Bring MS MindShift Initiative and “Brain Bulb” Hot Air Balloon to Festival to Raise Awareness of Multiple Sclerosis and Brain Health
7/24/2019
Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) are bringing the MS MindShift: A New View of MS initiative to the 37th Annual QuickChek New Jersey Festival of Ballooning in Readington, NJ, on July 26-28, where the MS MindShift “Brain Bulb” hot air balloon will fly to raise awareness of multiple sclerosis (MS) and brain health.
-
The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.
-
The FDA approval marks the first for oral ulcers associated with Behçet’s Disease and the third for Otezla.